Neue Antikoagulantien

Schlüsselwörter

direkte Antikoagulation - Thrombininhibition - Faktor-Xa-Inhibition

Keywords

direct anticoagulation - thrombin inhibitor - factor Xa inhibition

Literatur

• 1 Agnelli G, Gallus A, Goldhaber S Z, Haas S, Huisman M V, Hull R D, Kakkar A K, Misselwitz F, Schellong S. ODIXa-DVT Study Investigators . Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59 – 7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59 – 7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.  Circulation. 2007;  116 180-187
• 2 Buller H R, Lensing A W, Prins M H, Agnelli G, Cohen A, Gallus A S, Misselwitz F, Raskob G, Schellong S, Segers A. Einstein-DVT Dose-Ranging Study investigators . A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.  Blood. 2008;  112 2242-2247
• 3 Eriksson B I, Borris L C, Friedman R J, Haas S, Huisman M V, Kakkar A K, Bandel T J, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. RECORD1 Study Group . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.  New Engl J Med. 2008;  358 2765-2775
• 4 Eriksson B I, Dahl O E, Buller H R, Hettiarachchi R, Rosencher N, Bravo M L, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P. BISTRO II Study Group . A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.  Thrombos Haemost. 2005;  3 103-111
• 5 Eriksson B I, Dahl O E, Rosencher N, Kurth A A, van Dijk C N, Frostick S P, Prins M H, Hettiarachchi R, Hantel S, Schnee J, Buller H R. RE-NOVATE Study Group . Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement.  Lancet. 2007;  370 949-956
• 6 Ezekowitz M D, Reilly P A, Nehmiz G, Simmers T A, Nagarakanti R, Parcham-Azad K, Pedersen K E, Lionetti D A, Stangier J, Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).  Amer J Cardiol. 2007;  100 1419-1426
• 7 Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design.  Scand Cardiovasc J. 2000;  34 168-171
• 8 Kakkar A K, Brenner B, Dahl O E, Eriksson B I, Mouret P, Muntz J, Soglian A G, Pap A F, Misselwitz F, Haas S. RECORD2 Investigators . Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty.  Lancet. 2008;  372 31-39
• 9 Lassen M R, Ageno W, Borris L C, Lieberman J R, Rosencher N, Bandel T J, Misselwitz F, Turpie A G. RECORD3 Investigators . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.  New Engl J Med. 2008;  358 2776-2786
• 10 Mueck W, Eriksson B I, Bauer K A, Borris L, Dahl O E, Fisher W D, Gent M, Haas S, Huisman M V, Kakkar A K, Kalebo P, Kwong L M, Misselwitz F, Turpie A G. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgery.  Clin Pharmacokinetics. 2008;  47 203-16
• 11 Smith P. Oral anticoagulants are effective long-term after acute myocardial infarction.  J Intern Med. 1999;  245 383-7
• 12 Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.  Brit J Clin Pharmacol. 2007;  64 292-303
• 13 Wolowacz S E, Roskell N S, Plumb J M, Caprini J A, Eriksson B I. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.  Thrombos Haemost. 2009;  101 77-85